7-Geranyloxcycoumarin enhances radio sensitivity in human prostate cancer cells

Background Prostate cancer is the second most prevalent and the fifth deadliest cancer among men worldwide. To improve radiotherapy outcome, we investigated the effects of 7-geranyloxycoumarin, also known as auraptene (AUR), on radiation response of prostate cancer cells. Methods and results PC3 cel...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biology reports 2023-07, Vol.50 (7), p.5709-5717
Main Authors: Abolhassani, Yasaman, Mirzaei, Sara, Nejabat, Masoud, Talebian, Seyedehsaba, Gholamhosseinian, Hamid, Iranshahi, Mehrdad, Rassouli, Fatemeh B., Jamialahmadi, Khadijeh
Format: Article
Language:English
Subjects:
Animal Anatomy
Animal Biochemistry
Apoptosis
Biomedical and Life Sciences
Cell viability
Clinical trials
Flow cytometry
Histology
Life Sciences
Morphology
Original Article
Prostate cancer
Radiation
Radiation therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Prostate cancer is the second most prevalent and the fifth deadliest cancer among men worldwide. To improve radiotherapy outcome, we investigated the effects of 7-geranyloxycoumarin, also known as auraptene (AUR), on radiation response of prostate cancer cells. Methods and results PC3 cells were pretreated with 20 and 40 µM AUR for 24, 48 and 72 h, followed by X-ray exposure (2, 4 and 6 Gy). After 72 h recovery, cell viability was determined by alamar Blue assay. Flow cytometric analysis was performed to assess apoptosis induction, clonogenic assay was carried out to investigate clonogenic survival, and the expression of P53, BAX, BCL2, CCND1 and GATA6 was analyzed by quantitative polymerase chain reaction (qPCR). Cell viability assay indicated that toxic effects of radiation was enhanced by AUR, which was also confirmed by increased numbers of apoptotic cells and reduced amount of survival fraction. The qPCR results demonstrated significant induction of P53 and BAX , while the expression of BCL2, GATA6 , and CCND1 was significantly downregulated. Conclusion The findings of the present study indicated, for the first time, that AUR improved radio sensitivity in prostate cancer cells, and thus, has the potential to be used in future clinical trials.
ISSN:0301-4851
1573-4978
DOI:10.1007/s11033-023-08439-9